BlueCrest Capital Management’s Esperion Therapeutics ESPR Stock Holding History

BlueCrest Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,426	Closed	-$35.3K	–	242
2023 Q2	$35.3K	Hold	25,426	–	–	﹤0.01%	192
2023 Q1	$40.4K	Buy	+25,426	New	+$131K	﹤0.01%	257
2018 Q4	–	Sell	-6,942	Closed	-$308K	–	1033
2018 Q3	$308K	Buy	+6,942	New	+$319K	0.01%	1025
2017 Q4	–	Sell	-5,099	Closed	-$256K	–	899
2017 Q3	$256K	Buy	+5,099	New	+$246K	0.01%	677

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlueCrest Capital Management's ESPR Position: Q3 2023 in Review

BlueCrest Capital Management sold out of Esperion Therapeutics (ESPR) in Q3 2023, closing a stake of 25,426 shares — an estimated $35.3K sold.

BlueCrest Capital Management first reported a position in ESPR in Q3 2017 and held it in 4 quarters. The position peaked at $308K in Q3 2018. 122 funds tracked by Wall St. Rank hold ESPR as of Q3 2023.

BlueCrest Capital Management reported no remaining Esperion Therapeutics position as of Q3 2023 after selling out during the quarter.
BlueCrest Capital Management sold 25,426 Esperion Therapeutics shares in Q3 2023, an estimated $35.3K.
BlueCrest Capital Management first reported a position in Esperion Therapeutics in Q3 2017 and held it in 4 quarters.
BlueCrest Capital Management's Esperion Therapeutics position peaked at $308K in Q3 2018.
122 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2023.

Based on BlueCrest Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.